You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: HVMN Inc. Topic: SOCOM17C001
During altitude-induced hypoxia, operator cognitive and physical capacity degrades, compromising individual and team performance. Cognitive degradation is linked to falling brain energy levels, increased reliance on anaerobic energy production and lactate accumulation. Ketones are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies demonstrated that ...STTR Phase II 2019 Department of DefenseSpecial Operations Command
SBC: REJUVENATE BIO INC Topic: SOCOM17C001
Special OperationsForces (SOF)are an integral aspect of the US military. SOF operators are among the most elite and highly qualified individuals in the U.S.military. As such, extraordinary physical and mental demands are placed upon them to excel in extreme environments for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the funct ...STTR Phase II 2019 Department of DefenseSpecial Operations Command
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAID
DESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: COLLABORATIVE DRUG DISCOVERY, INC. Topic: NIAID
DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB co ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract InfectionsSBC: Combinati Incorporated Topic: NIAID
Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Tfc Consultants, Inc. Topic: NIMH
DESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOINVISION INC Topic: NICHD
DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Yecuris Corporation Topic: NCRR
DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Cetya Therapeutics, Inc. Topic: NHLBI
PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VALA SCIENCES, INC. Topic: NCI
DESCRIPTION (provided by applicant): The proposed project is a Phase I STTR collaboration between Vala Sciences Inc, a small business that specializes in the development of cell-based high content/high throughput assays, and the Sanford Burnham Medical Research Institute, a worldwide leader in biomedical research. The project will develop an assay (Kinetic Image Cytometer-Neuron, or KIC-Neuron) to ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health